Creo Medical Group PLC Acquisition of freehold site for GBP4.25m (7133B)

TIDMCREO

RNS Number : 7133B

Creo Medical Group PLC

14 June 2021

Creo Medical Group plc

("Creo" or the "Company")

Acquisition of freehold site for GBP4.25m

Expansion of Chepstow footprint to support commercial roll-out

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has exchanged contracts to acquire the freehold interest in the current site of Creo House, the Company's main headquarters in Chepstow ('Unit 2'), as well as the adjacent site ('Units 6-9') for a total consideration of GBP4.25 million in cash. Creo expects to complete the acquisition in early July.

Creo House has current total capacity of approximately 18,000 sq ft and the adjacent site, subject to receiving planning permission, will provide an additional 16,000 sq. ft. of increased capacity. This additional capacity will support Creo's commercial, operational and logistic footprint across Europe (following the acquisition of Albyn Medical S.L. in July and Boucart Medical SRL in November 2020) and will also provide additional manufacturing capacity for the commercial roll-out of the full range of products from the Creo GI (gastro-intestinal) suite of advanced energy devices which complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy.

The freehold will be acquired from Fastnet Property Investments Limited, the original developer of the site.

Craig Gulliford, Chief Executive Officer of Creo, commented: " We are delighted to have secured the freehold of Creo House as well as the adjacent site which, subject to planning permission, will provide increased capacity to support our commercial, operational and logistic footprint across Europe; as well as providing additional manufacturing capacity for the commercial roll-out of the full suite of advanced energy devices. By acquiring these sites, we are not only showing a firm commitment to Wales, but we are also giving our workforce even greater stability. The expansion is reflective of the rapid growth within Creo ."

Enquires:

 
 Creo Medical Group plc                                          investors.creomedical.com 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities plc                                                 [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne                    Mob: [phone] 
                                                                                   909 238 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQGPURUQUPGGWP

(END) Dow Jones Newswires

June 14, 2021 02:00 ET (06:00 GMT)